Extended Observation of Tislelizumab and Anlotinib Combination Therapy in a Patient with Metastatic Type B3 Thymoma: A Case Study

1

Thymoma is a rare malignancy with Type B3 associated with poor prognosis and limited effective systemic therapies.
2

A middle-aged woman with metastatic type B3 thymoma showed significant response to tislelizumab and anlotinib after failing platinum-based chemotherapy.
3

The patient experienced over 30 months of progression-free survival and maintained a good quality of life during the treatment.
4

High PD-L1 expression was noted in the tumor, indicating potential responsiveness to immune checkpoint inhibitors.
5

Further prospective studies with larger cohorts are needed to validate the efficacy and safety of tislelizumab and anlotinib in thymoma.

1